Correction to: Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials

Blanchard, Clara; Paul, Vanaja; Denis, Pouchain; Mignot, Stéphanie; Vaillant-Roussel, Hélène; Boussageon, Rémy

doi:10.1007/s00228-019-02793-z

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the pharmacodynamics of phloroglucinol are not yet clearly elucidated, it is considered to directly relax smooth muscle by inhibiting voltage-dependent calcium channels [ 19 ]. Based on its spasmolytic activity, phloroglucinol has been investigated in various diseases to treat spasmodic pain and irritable bowel syndrome (IBS) [ 20 – 22 ]. Despite the widespread prescription of phloroglucinol, especially in Europe, data to support its clinical utility are limited [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of oral phloroglucinol as a premedication for unsedated esophagogastroduodenoscopy: A prospective, double-blinded, placebo-controlled, randomized trial

et al. 2021

View full text Add to dashboard Cite

Background Anti-spasmodic agents are commonly injected during esophagogastroduodenoscopy (EGD) to improve visualization of the gastric mucosa by inhibiting gastrointestinal (GI) peristalsis. The availability of oral anti-spasmodic agents would increase convenience. In this study, we evaluated the effectiveness of oral phloroglucinol (Flospan®) as a premedication for unsedated EGD. Methods A prospective, double-blinded, placebo-controlled, randomized controlled trial was conducted in a tertiary hospital. Individuals scheduled to undergo unsedated EGD were randomly assigned to receive either oral phloroglucinol or matching placebo 15 min before EGD. The primary outcome was the rate of complete gastric peristalsis suppression. Outcomes were assessed by independent investigators according to the classification of gastric peristalsis and ease of intragastric observation at the beginning (Period A) and end (Period B) of EGD. Results Overall, 71 phloroglucinol-treated and 71 placebo-treated participants (n = 142 total) were included. The phloroglucinol group showed significantly higher proportions of participants with complete gastric peristalsis suppression than the placebo group (22.5% vs. 9.9%, P = 0.040). The ease of intragastric observation was significantly better in the phloroglucinol group than in the placebo group at Periods A (P < 0.001) and B (P = 0.005). Patients in both groups had comparable adverse events and showed willingness to take the premedication at their next examination. Conclusions Oral phloroglucinol significantly suppressed gastrointestinal peristalsis during unsedated EGD compared with placebo (Clinical trial registration number: NCT03342118).

show abstract

Section: Discussionmentioning

confidence: 99%